medvi reviews
Last updated: June 23, 2026
Quick Answer: MEDVi is a telehealth platform offering compounded semaglutide and tirzepatide injections and oral tablets for weight loss, starting as low as $149 for the first month. Most medvi reviews highlight affordable pricing and easy online access, but a February 2026 FDA warning letter and some billing complaints are worth knowing before you sign up.
Key Takeaways
- MEDVi offers compounded GLP-1 medications (semaglutide and tirzepatide) at significantly lower prices than brand-name Wegovy or Zepbound
- First-month pricing starts at $149 for compounded semaglutide injections, rising to $297-$299/month ongoing [3][4]
- Tirzepatide injections start at $279-$349 for month one, then $399-$499/month depending on dose [4][2]
- MEDVi received an FDA warning letter in February 2026 related to compounded GLP-1 medications, a regulatory development all prospective patients should review
- Trustpilot ratings for MEDVi are generally positive, with many users reporting meaningful weight loss within the first 8-12 weeks [1]
- Common complaints include billing confusion, slow customer service responses, and unclear cancellation policies [7][6]
- MEDVi does not accept insurance, so all costs are out-of-pocket
- The platform is best suited for adults with a BMI of 27 or higher who want affordable GLP-1 access without a traditional clinic visit
Our Rating: 4.1/5 – Recommended With Caution
Best for: Adults seeking affordable compounded GLP-1 medications without insurance
Best for: People who prefer telehealth over in-person clinic visits
Best for: Patients who have already tried lifestyle changes alone
Skip if: You are pregnant, nursing, or have a personal or family history of medullary thyroid cancer
Skip if: You want brand-name Wegovy or Zepbound covered by insurance
What Is MEDVi and How Does the GLP-1 Program Work?
MEDVi is a U.S.-based telehealth company that connects patients with licensed providers who can prescribe compounded GLP-1 receptor agonist medications for weight loss. The platform operates entirely online, meaning you complete an intake form, consult with a clinician via messaging or video, and receive medication shipped directly to your door.
The two main medications offered are:
- Compounded semaglutide (the active ingredient in Ozempic and Wegovy)
- Compounded tirzepatide (the active ingredient in Mounjaro and Zepbound)
Both are available as self-injectable pens or oral tablets, depending on patient preference and clinical appropriateness.
How GLP-1 medications work: These drugs mimic the glucagon-like peptide-1 hormone, which signals the brain to feel full, slows gastric emptying, and reduces appetite. Clinical trials for semaglutide have shown average weight loss of around 15% of body weight over 68 weeks (New England Journal of Medicine, semaglutide weight loss trial data). Tirzepatide, a dual GIP/GLP-1 agonist, has shown even higher average weight loss in trials (SURMOUNT-1 trial data, published in NEJM).
MEDVi’s compounded versions are not FDA-approved drugs themselves, but they contain the same active pharmaceutical ingredients produced by FDA-registered compounding pharmacies.
MEDVi Reviews: What Do Real Customers Say?
The overall picture from medvi reviews across multiple platforms is cautiously positive, though not without real concerns.
On Trustpilot, MEDVi holds a rating that reflects a mix of strong weight-loss success stories and frustration with customer service and billing [1]. Positive reviews frequently mention:
- Noticeable appetite suppression within the first 2-3 weeks
- Weight loss of 10-25 lbs reported within the first 2-3 months
- Convenient online process with no in-person visits required
- Medication arriving quickly after approval
Negative reviews and complaints tend to cluster around:
- Unexpected charges after the introductory period [7]
- Difficulty reaching customer support to cancel or modify subscriptions [6]
- Some patients reporting nausea and gastrointestinal side effects, which are common with GLP-1 medications generally
- Confusion about dose escalation schedules [5]
On ConsumerAffairs, similar themes emerge: patients who stay on the program and manage side effects tend to report solid results, while those who encounter billing issues express significant frustration [7].
Bottom line on reviews: MEDVi appears to deliver on its core promise of affordable GLP-1 access for many users, but the billing and support experience is inconsistent enough that you should read the subscription terms carefully before enrolling.
MEDVi Pricing in 2026: Is It Actually Affordable?
MEDVi markets itself as one of the most affordable GLP-1 telehealth options available, and the pricing does undercut brand-name alternatives significantly.
| Medication | First Month | Ongoing Monthly |
|---|---|---|
| Compounded Semaglutide (injection) | $149-$179 | $297-$299 |
| Semaglutide Oral Tablets | $249 | $349-$369 |
| Compounded Tirzepatide (injection) | $279-$349 | $399-$499 |
| Tirzepatide Oral Tablets | $279-$349 | ~$399 |
Sources: [3][4][2]
For comparison, brand-name Wegovy (semaglutide) retails at over $1,300/month without insurance, and Zepbound (tirzepatide) is similarly priced. MEDVi’s compounded semaglutide at $297/month represents roughly a 75-80% cost reduction versus the brand-name equivalent.
Who benefits most from MEDVi’s pricing:
- Adults without insurance coverage for GLP-1 medications
- People who have been denied prior authorization for brand-name drugs
- Those who want to try GLP-1 therapy before pursuing brand-name options
For a broader look at how GLP-1 costs compare across platforms, see our GLP-1 price per month comparison for 2026.
The February 2026 FDA Warning Letter: What It Means for MEDVi Patients
In February 2026, the FDA issued a warning letter to MEDVi related to its compounded GLP-1 medications. This is a significant regulatory development that every prospective patient should understand.
What the warning letter addressed: The FDA has been tightening oversight of compounded semaglutide and tirzepatide products across the telehealth industry as the shortage status of brand-name GLP-1 drugs has evolved. Warning letters in this space typically relate to compounding practices, marketing claims, or the legal basis for compounding once a drug is no longer on the FDA shortage list.
What this means practically:
- Compounded semaglutide and tirzepatide exist in a regulatory gray area; they are not FDA-approved finished drug products
- The FDA warning does not mean MEDVi’s medications are proven unsafe, but it does signal regulatory scrutiny
- Patients should ask their MEDVi provider directly about the current status of their compounding pharmacy and any changes to the medication program
What to do: If you are already a MEDVi patient, consult with your prescribing provider about whether your current medication supply is affected. If you are considering enrolling, factor this regulatory context into your decision.
For context on how other compounded GLP-1 platforms handle similar issues, see our AltRx GLP-1 review and Refills GLP-1 review.
MEDVi vs. Competitors: How Does It Compare?
Medvi reviews often compare the platform against other telehealth GLP-1 providers. Here is how MEDVi stacks up against two close competitors.
| Feature | MEDVi | Measured | Shed |
|---|---|---|---|
| Compounded Semaglutide (monthly) | $297-$299 | Varies | Varies |
| Compounded Tirzepatide (monthly) | $399-$499 | Varies | Varies |
| Insurance Accepted | No | No | No |
| Oral Tablet Option | Yes | Yes | Limited |
| FDA Warning (2026) | Yes | Not confirmed | Not confirmed |
| Trustpilot Presence | Yes | Limited | Limited |
| Cancellation Policy | Subscription-based | Subscription-based | Subscription-based |
MEDVi’s pricing is competitive, particularly for tirzepatide. However, the February 2026 FDA warning letter is a differentiating factor that competitors have not publicly faced at the same level.
For a detailed look at another option, read our Measured GLP-1 review and our Shed GLP-1 reviews.
Choose MEDVi if: You want the lowest possible entry price for compounded semaglutide and you are comfortable with the regulatory context.
Choose a competitor if: Regulatory certainty is your top priority, or you want a platform with a longer track record.
MEDVi’s 30-Day Experience: What to Realistically Expect
Based on aggregated patient reports from medvi reviews across Trustpilot, ConsumerAffairs, and independent review sites, here is what a typical first month on MEDVi looks like [1][6][7].
Week 1: Most patients report little to no appetite change. The starting dose of compounded semaglutide is low by design. Some notice mild nausea or fatigue, which is standard for GLP-1 initiation.
Week 2: Appetite suppression begins to appear for many users. Nausea may peak around this point. Staying hydrated and eating smaller meals helps significantly.
Weeks 3-4: The majority of patients who tolerate the medication report noticeably reduced hunger and early weight loss, often 3-6 lbs in the first month at the starting dose.
Pros of MEDVi:
- Low first-month cost lowers financial risk
- Fully online process saves time
- Oral tablet option available for needle-averse patients
- Compounded tirzepatide pricing is competitive
- Dose escalation managed by licensed providers
Cons of MEDVi:
- FDA warning letter in February 2026 creates regulatory uncertainty
- Billing complaints are a recurring theme in reviews
- Customer service response times can be slow
- No insurance accepted, so all costs are out-of-pocket
- Results vary significantly based on dose, diet, and adherence
Is MEDVi Legitimate and Safe?
MEDVi operates with licensed healthcare providers and uses FDA-registered compounding pharmacies, which places it within the legal framework for telehealth prescribing in the U.S. [8][9]. However, “legitimate” and “risk-free” are not the same thing.
Safety considerations:
- GLP-1 medications carry real side effects: nausea, vomiting, diarrhea, constipation, and in rare cases more serious events like pancreatitis
- Compounded medications are not individually FDA-approved, meaning quality control depends on the compounding pharmacy rather than the FDA’s drug approval process
- The February 2026 FDA warning letter is a genuine regulatory flag, not a minor administrative issue
Who should not use MEDVi:
- Pregnant or breastfeeding individuals
- People with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Anyone with a history of pancreatitis (discuss with your doctor first)
- People currently on medications with significant GLP-1 interaction risks
If you are curious about how oral semaglutide options specifically work, our semaglutide tablets review covers the science and current evidence in detail.
Billing, Cancellation, and Common “Gotchas”
This is where medvi reviews get most heated. The platform uses a subscription model, and several users report being charged for subsequent months without clear warning [6][7].
Key billing facts to know:
- The introductory price ($149-$179 for semaglutide) applies to month one only
- Month two pricing jumps to $297-$299 for semaglutide injections, which represents a significant increase
- Cancellation must typically be initiated before the next billing cycle, and some users report difficulty reaching support in time [5]
- Refund policies are not universally applied, based on complaint patterns seen in ConsumerAffairs reviews [7]
How to protect yourself:
- Read the full subscription terms before entering payment information
- Set a calendar reminder 7-10 days before your next billing date
- Contact support via email and keep a written record of all communications
- Ask explicitly about the cancellation window and refund policy at enrollment
Frequently Asked Questions About MEDVi
Is MEDVi a legitimate company?
Yes, MEDVi is a real telehealth company with licensed providers and FDA-registered compounding pharmacies. However, it received an FDA warning letter in February 2026, which is a regulatory concern prospective patients should research before enrolling.
How much does MEDVi cost per month in 2026?
Compounded semaglutide injections cost $149-$179 for month one, then $297-$299/month ongoing. Tirzepatide injections start at $279-$349 for month one, then $399-$499/month depending on dose. [3][4][2]
Does MEDVi accept insurance?
No. MEDVi does not accept insurance. All costs are paid out-of-pocket.
How quickly does MEDVi ship medication?
Most patient reports indicate medication arrives within 5-10 business days of prescription approval, though shipping times can vary by location.
What is the difference between MEDVi’s semaglutide and Wegovy?
Both contain semaglutide as the active ingredient. Wegovy is an FDA-approved brand-name drug. MEDVi’s version is a compounded product from an FDA-registered pharmacy, which is not individually FDA-approved but is significantly cheaper.
Can I cancel MEDVi at any time?
Technically yes, but multiple reviews report difficulty with the cancellation process. Contact support well before your next billing date and keep written records of all communications. [6][7]
What side effects are most commonly reported in MEDVi reviews?
Nausea, reduced appetite, fatigue, and gastrointestinal discomfort (bloating, constipation, or diarrhea) are the most commonly reported side effects, consistent with GLP-1 medications generally. [6][5]
Does MEDVi offer tirzepatide?
Yes. MEDVi offers compounded tirzepatide injections and oral tablets, starting at $279-$349 for the first month. [4][2]
Is MEDVi Semaglutide the most affordable tirzepatide option available?
MEDVi’s tirzepatide pricing is among the most competitive in the telehealth market for compounded versions, though pricing varies by dose and platform. Comparing multiple providers before committing is always advisable.
What happened with MEDVi’s FDA warning letter?
In February 2026, the FDA issued a warning letter to MEDVi related to its compounded GLP-1 medications. The full details of the letter relate to compounding regulations as the FDA has tightened oversight across the industry. Patients should ask MEDVi directly about how this affects their current program.
How does MEDVi compare to other GLP-1 telehealth platforms?
MEDVi is price-competitive, especially for first-month semaglutide. Its main differentiators are low entry cost and oral tablet availability. The FDA warning letter and billing complaints are its main weaknesses versus competitors.
Who is MEDVi best for?
MEDVi is best for adults with a BMI of 27 or higher who want affordable compounded GLP-1 access, do not have insurance coverage for weight-loss medications, and are comfortable managing a telehealth subscription model.
Conclusion: Should You Try MEDVi in 2026?
MEDVi delivers on its core value proposition: affordable, accessible compounded GLP-1 medications for adults who cannot or do not want to pay brand-name prices. For many users, the platform has produced real, meaningful weight loss results at a fraction of the cost of Wegovy or Zepbound.
That said, the February 2026 FDA warning letter is not something to dismiss. It reflects genuine regulatory tension around compounded GLP-1 medications industry-wide, and MEDVi is not immune to that scrutiny.
Actionable next steps:
- Confirm you are a candidate for GLP-1 therapy (BMI 27+ with a weight-related condition, or BMI 30+)
- Review MEDVi’s current subscription and cancellation terms before entering payment information
- Ask your MEDVi provider directly about the compounding pharmacy status following the 2026 FDA letter
- Set billing reminders to avoid unexpected charges after the introductory month
- Track your weight, appetite, and any side effects weekly so you can make an informed decision about continuing
If you decide MEDVi is not the right fit, our reviews of AltRx GLP-1 and Refills GLP-1 cover comparable alternatives at similar price points.
Get Started With MEDVi Semaglutide at the Lowest Price Available
References
[1] Medvi – https://www.trustpilot.com/review/medvi.org
[2] Medvi Reviews – https://peptidesexplorer.com/blog/medvi-reviews
[3] Medvi – https://manytreatments.com/brands/medvi
[4] Medvi Review – https://clearmetabolic.com/reviews/medvi-review/
[5] Medvi Reviews – https://www.medicinehack.com/medvi-reviews.html
[6] Medvi Reviews Complaints Side Effects Results What Patients Reveal In 2026 – https://yourhealthmagazine.net/article/reviews/medvi-reviews-complaints-side-effects-results-what-patients-reveal-in-2026/
[7] Medvi – https://www.consumeraffairs.com/health/medvi.html
[8] Medvi Reviews – https://therxindex.com/guides/medvi-reviews/
[9] Medvi Review 2026 – https://formblends.com/es/articles/comparison-hub/medvi-review-2026
[10] Medvi – https://ie.trustpilot.com/review/medvi.org?page=6
Tags: medvi reviews, GLP-1 telehealth, compounded semaglutide, compounded tirzepatide, weight loss telehealth, semaglutide cost 2026, tirzepatide pricing, MEDVi semaglutide, GLP-1 alternatives, telehealth weight loss, Wegovy alternative, affordable GLP-1
